Research programme: glycogen synthase inhibitors - Dover Lifesciences
Latest Information Update: 28 Aug 2020
Price :
$50 *
At a glance
- Originator Dover Lifesciences
- Class Small molecules
- Mechanism of Action Glucosyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lysosomal storage diseases; Prader-Willi syndrome
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Lysosomal storage diseases in USA
- 28 Aug 2020 No recent reports of development identified for research development in Prader-Willi-syndrome in USA
- 13 Jul 2016 Early research in Lysosomal storage diseases in USA (unspecified route)